VIALE, GIUSEPPE
VIALE, GIUSEPPE
Dipartimento di Oncologia ed Emato-Oncologia
Immune microenvironment dynamics in breast cancer during pregnancy: impact of gestational age on tumor-infiltrating lymphocytes and prognosis
2023 E. Sajjadi, K. Venetis, M. Ivanova, M. Noale, C. Blundo, E. Di Loreto, G. Scarfone, S. Ferrero, S. Maggi, P. Veronesi, V.E. Galimberti, G. Viale, F.A. Peccatori, N. Fusco, E. Guerini-Rocco
ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing Hormone Receptor-positive, HER2-negative breast cancer (HR+ HER2- BC)
2023 L. Ferrando, A. Vingiani, A. Garuti, C. Vernieri, A. Belfiore, L. Agnelli, G. Dagrada, D. Ivanoiu, G. Bonizzi, E. Munzone, L. Lippolis, M. Dameri, F. Ravera, M. Colleoni, G. Viale, L. Magnani, A. Ballestrero, G. Zoppoli, G. Pruneri
Tucatinib's journey from clinical development to clinical practice: New horizons for HER2-positive metastatic disease and promising prospects for brain metastatic spread
2023 C. Criscitiello, C. Corti, M. De Laurentiis, G. Bianchini, B. Pistilli, S. Cinieri, L. Castellan, G. Arpino, P. Conte, F. DI MECO, A. Gennari, V. Guarneri, L. Visani, L. Livi, P. Marchetti, F. Puglisi, G. Viale, L. Del Mastro, S. De Placido, G. Curigliano
TMEM123 a key player in immune surveillance of colorectal cancer
2023 E. Pesce, C. Cordiglieri, M. Bombaci, S. Eppenberger-Castori, S. Oliveto, C. Manara, M. Crosti, C. Ercan, M. Coto, A. Gobbini, S. Campagnoli, T. Donnarumma, M. Martinelli, V. Bevilacqua, E. De Camilli, P. Gruarin, M.L. Sarnicola, E. Cassinotti, L. Baldari, G. Viale, S. Biffo, S. Abrignani, L.M. Terracciano, R. Grifantini
Efficacy of Alternative Dose Regimens of Exemestane in Postmenopausal Women With Stage 0 to II Estrogen Receptor-Positive Breast Cancer: A Randomized Clinical Trial
2023 D. Serrano, S. Gandini, P. Thomas, K.D. Crew, N.B. Kumar, L.A. Vornik, J.J. Lee, P. Veronesi, G. Viale, A. Guerrieri-Gonzaga, M. Lazzeroni, H. Johansson, M. D'Amico, F. Guasone, S. Spinaci, B. Bertelsen, G. Mellgren, I. Bedrosian, D. Weber, T. Castile, E. Dimond, B.M. Heckman-Stoddard, E. Szabo, P.H. Brown, A. Decensi, B. Bonanni
Advances in Early Breast Cancer Risk Profiling: From Histopathology to Molecular Technologies
2023 C. Pescia, E. Guerini-Rocco, G. Viale, N. Fusco
Effects of neoadjuvant trastuzumab, pertuzumab and palbociclib on Ki67 in HER2 and ER-positive breast cancer
2022 L. Gianni, M. Colleoni, G. Bisagni, M. Mansutti, C. Zamagni, L. Del Mastro, S. Zambelli, G. Bianchini, A. Frassoldati, I. Maffeis, P. Valagussa, G. Viale
Pathology after neoadjuvant treatment – How to assess residual disease
2022 G. Viale, N. Fusco
Systematically higher Ki67 scores on core biopsy samples compared to corresponding resection specimen in breast cancer: a multi-operator and multi-institutional study
2022 B. Acs, S.C.Y. Leung, K.M. Kidwell, I. Arun, R. Augulis, S.S. Badve, Y. Bai, A.L. Bane, J.M.S. Bartlett, J. Bayani, G. Bigras, A. Blank, H. Buikema, M.C. Chang, R.L. Dietz, A. Dodson, S. Fineberg, C.M. Focke, D. Gao, A.M. Gown, C. Gutierrez, J. Hartman, Z. Kos, A.-. Laenkholm, A. Laurinavicius, R.M. Levenson, R. Mahboubi-Ardakani, M.G. Mastropasqua, S. Nofech-Mozes, C.K. Osborne, F.M. Penault-Llorca, T. Piper, M.A. Quintayo, T.T. Rau, S. Reinhard, S. Robertson, R. Salgado, T. Sugie, B. van der Vegt, G. Viale, L.A. Zabaglo, D.F. Hayes, M. Dowsett, T.O. Nielsen, D.L. Rimm
Standard operating procedures for biobank in oncology
2022 G. Bonizzi, L. Zattoni, M. Capra, C. Cassi, G. Taliento, M. Ivanova, E. Guerini-Rocco, M. Fumagalli, M. Monturano, A. Albini, G. Viale, R. Orecchia, N. Fusco
Role and evaluation of pathologic response in early breast cancer specimens after neoadjuvant therapy: consensus statement
2022 E. Guerini-Rocco, G. Botti, M.P. Foschini, C. Marchio, M.G. Mastropasqua, G. Perrone, E. Roz, A. Santinelli, I. Sassi, V. Galimberti, L. Gianni, G. Viale
LINE1 are spliced in non-canonical transcript variants to regulate T cell quiescence and exhaustion
2022 F. Marasca, S. Sinha, R. Vadala, B. Polimeni, V. Ranzani, E.M. Paraboschi, F.V. Burattin, M. Ghilotti, M. Crosti, M.L. Negri, S. Campagnoli, S. Notarbartolo, A. Sartore-Bianchi, S. Siena, D. Prati, G. Montini, G. Viale, O. Torre, S. Harari, R. Grifantini, G. Solda, S. Biffo, S. Abrignani, B. Bodega
Outcome of patients with metastatic triple negative breast cancer treated with first-line chemotherapy: a single institution retrospective analysis
2022 N. Bianco, M. Milano, E. Pagan, C. Oriecuia, V. Bagnardi, E.G. Rocco, G.I. Santomauro, G. Peruzzotti, M. Colleoni, G. Viale
HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer
2022 K. Venetis, E. Crimini, E. Sajjadi, C. Corti, E. Guerini-Rocco, G. Viale, G. Curigliano, C. Criscitiello, N. Fusco
The prolonged clinical benefit with metronomic chemotherapy (VEX regimen) in metastatic breast cancer patients
2022 E. Montagna, E. Pagan, G. Cancello, C. Sangalli, V. Bagnardi, E. Munzone, E.O. Salè, D. Malengo, M.E. Cazzaniga, M. Negri, G. Peruzzotti, P. Veronesi, G. Viale, M. Colleoni
Definition of High-Risk Early Hormone-Positive HER2-Negative Breast Cancer: A Consensus Review
2022 M. Garutti, G. Griguolo, A. Botticelli, G. Buzzatti, C. De Angelis, L. Gerratana, C. Molinelli, V. Adamo, G. Bianchini, L. Biganzoli, G. Curigliano, M. De Laurentiis, A. Fabi, A. Frassoldati, A. Gennari, C. Marchiò, F. Perrone, G. Viale, C. Zamagni, A. Zambelli, L. Del Mastro, S. De Placido, V. Guarneri, P. Marchetti, F. Puglisi
CDK12 promotes tumorigenesis but induces vulnerability to therapies inhibiting folate one- carbon metabolism in breast cancer
2022 M.G. Filippone, D. Gaglio, R. Bonfanti, F.A. Tucci, E. Ceccacci, R. Pennisi, M. Bonanomi, G. Jodice, M. Tillhon, F. Montani, G. Bertalot, S. Freddi, M. Vecchi, A. Taglialatela, M. Romanenghi, F. Romeo, N. Bianco, E. Munzone, F. Sanguedolce, G. Vago, G. Viale, P.P. Di Fiore, S. Minucci, L. Alberghina, M. Colleoni, P. Veronesi, D. Tosoni, S. Pece
Determining PD-L1 Status in Patients With Triple-Negative Breast Cancer: Lessons Learned From IMpassion130
2022 S.S. Badve, F. Penault-Llorca, J.S. Reis-Filho, R. Deurloo, K.P. Siziopikou, C. D'Arrigo, G. Viale
Breast Cancer during Pregnancy as a Special Type of Early-Onset Breast Cancer: Analysis of the Tumor Immune Microenvironment and Risk Profiles
2022 E. Sajjadi, K. Venetis, M. Noale, H.A. Azim, C. Blundo, G. Bonizzi, E. Di Loreto, G. Scarfone, S. Ferrero, S. Maggi, M. Barberis, P. Veronesi, V.E. Galimberti, G. Viale, N. Fusco, F.A. Peccatori, E. Guerini-Rocco
Comparison of HercepTest™ mAb pharmDx (Dako Omnis, GE001) with Ventana PATHWAY anti-HER-2/neu (4B5) in breast cancer: correlation with HER2 amplification and HER2 low status
2022 J. Rüschoff, M. Friedrich, I. Nagelmeier, M. Kirchner, L.M. Andresen, K. Salomon, B. Portier, S.T. Sredni, H.U. Schildhaus, B. Jasani, M. Grzelinski, G. Viale